Synaffix BV is a biotech company that has established a proprietary, clinical-stage technology platform that enables best-in-class antibody-drug conjugates (ADCs) in terms of safety and efficacy. Our technology out-licensing business has already translated into 3 clinical-stage ADCs, at least 15 distinct ADC programs being developed across our 10 partners and over $5.75Bn in total potential value from our out-licensing deals. Our partners include top-tier biotech and pharma companies such as ADC Therapeutics, Mersana Therapeutics, Janssen, Shanghai Miracogen, Innovent Biologics, ProfoundBio, Kyowa Kirin, Genmab, Macrogenics, Emergence Therapeutics, Hummingbird Bioscience and Amgen. Synaffix offers a consolidated ADC platform technology that enables any company with an antibody to develop a proprietary, best-in-class ADC and our patent portfolio provides granted protection of any resulting Products through at least 2035. Rather than developing a pipeline of our own drugs, the business model of Synaffix is technology out-licensing where we regularly engage in discovery research collaborations with companies that are interested in developing highly competitive ADC Products using our proprietary technology.